Key Points
- Insider sale: Mittie Doyle sold 679 Avalo Therapeutics shares at $20 each for $13,580 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 1.29% to 51,776 shares. She also sold shares in June and July.
- Operating performance: AVTX opened at $18.95 after declining 2%, while the company reported a quarterly loss of $0.83 per share, missing the $0.58 analyst consensus estimate.
- Analyst sentiment remains positive: Thirteen analysts rate the stock Buy versus one Sell, producing a “Moderate Buy” consensus and an average price target of $45.10; institutional investors own 87.06% of the shares.
Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the business's stock in a transaction on Friday, August 28th. The stock was sold at an average price of $20.00, for a total value of $13,580.00. Following the sale, the insider owned 51,776 shares of the company's stock, valued at approximately $1,035,520. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mittie Doyle also recently made the following trade(s):
- On Monday, July 27th, Mittie Doyle sold 1,000 shares of Avalo Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00.
- On Tuesday, June 23rd, Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00.
Avalo Therapeutics Stock Down 2.0%
AVTX stock opened at $18.95 on Wednesday. Avalo Therapeutics, Inc. has a twelve month low of $8.65 and a twelve month high of $24.27. The company has a market cap of $1.02 billion, a P/E ratio of -4.34 and a beta of 0.78. The business's fifty day moving average is $19.05 and its 200-day moving average is $16.85.
Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.25). Research analysts anticipate that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have recently commented on AVTX. Citizens Jmp lowered their price target on Avalo Therapeutics from $62.00 to $55.00 and set a "market outperform" rating for the company in a research note on Thursday, May 14th. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They set an "outperform" rating and a $38.00 price objective for the company. Piper Sandler reaffirmed an "overweight" rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Wedbush cut their target price on shares of Avalo Therapeutics from $40.00 to $34.00 and set an "outperform" rating on the stock in a report on Thursday, May 14th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $45.10.
View Our Latest Analysis on AVTX
Institutional Investors Weigh In On Avalo Therapeutics
Hedge funds have recently modified their holdings of the business. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the 2nd quarter valued at about $56,000. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics in the third quarter valued at approximately $143,000. AlphaCentric Advisors LLC bought a new stake in shares of Avalo Therapeutics during the first quarter worth $174,000. California State Teachers Retirement System bought a new stake in shares of Avalo Therapeutics during the second quarter worth $196,000. Finally, Jump Financial LLC bought a new stake in Avalo Therapeutics in the 4th quarter valued at $238,000. Institutional investors and hedge funds own 87.06% of the company's stock.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.
Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
